Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017–03 phase 2 trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical and Translational Radiation Oncology Année : 2023

Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017–03 phase 2 trial

Résumé

The STEREO POSTOP GORTEC 2017-03 phase 2 trial (NCT03401840) evaluates postoperative stereotactic body radiotherapy (SBRT) in case of high-risk margins for pT1-T2/N0 oropharyngeal and oral cavity tumors. The present ancillary study aimed to compare the dosimetric impact of adding non-coplanar arcs to the volumetric modulated arc therapy (VMAT) technique and to evaluate acute toxicities on the first patients included in this trial.

Domaines

Cancer

Dates et versions

hal-03889453 , version 1 (08-12-2022)

Identifiants

Citer

Julian Biau, Laura Lopez, Emilie Thivat, Mélanie Casile, Corinne Millardet, et al.. Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017–03 phase 2 trial. Clinical and Translational Radiation Oncology, 2023, 38, pp.169-174. ⟨10.1016/j.ctro.2022.11.007⟩. ⟨hal-03889453⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More